These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8586153)

  • 1. Effect of Tolrestat on oesophageal transit time and cholecystic motility in type 2 diabetic patients with asymptomatic diabetic neuropathy.
    Fabiani F; De Vincentis N; Staffilano A
    Diabete Metab; 1995 Dec; 21(5):360-4. PubMed ID: 8586153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tolrestat in the therapy of diabetic peripheral neuropathy: is this drug really useful?].
    Daniele E; Coco MP
    Clin Ter; 1995 Dec; 146(12):793-99. PubMed ID: 8681499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolrestat for mild diabetic neuropathy. A 52-week, randomized, placebo-controlled trial.
    Giugliano D; Marfella R; Quatraro A; De Rosa N; Salvatore T; Cozzolino D; Ceriello A; Torella R
    Ann Intern Med; 1993 Jan; 118(1):7-11. PubMed ID: 8416161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment with an aldose reductase inhibitor in peripheral neuropathy in elderly diabetic patients].
    Terranova R; Luca S
    Minerva Med; 1993 Sep; 84(9):461-6. PubMed ID: 8247317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement].
    Shimada H; Miki T; Kyogoku I; Kawagishi T; Inaba M; Okuno Y; Nishizawa Y; Morii H
    No To Shinkei; 1998 Sep; 50(9):817-20. PubMed ID: 9789304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction of nerve conduction and endoneurial blood flow deficits by the aldose reductase inhibitor, tolrestat, in diabetic rats.
    Cotter MA; Cameron NE; Hohman TC
    J Peripher Nerv Syst; 1998; 3(3):217-23. PubMed ID: 10959252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of hyperglycemia and the aldose reductase inhibitor tolrestat on sural nerve biochemistry and morphometry in advanced diabetic peripheral polyneuropathy. The Tolrestat Study Group.
    Sima AA; Greene DA; Brown MB; Hohman TC; Hicks D; Graepel GJ; Bochenek WJ; Beg M; Gonen B
    J Diabetes Complications; 1993; 7(3):157-69. PubMed ID: 8343610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: effect on nerve function. The Tolrestat Study Group.
    Santiago JV; Snksen PH; Boulton AJ; Macleod A; Beg M; Bochenek W; Graepel GJ; Gonen B
    J Diabetes Complications; 1993; 7(3):170-8. PubMed ID: 8343611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of tolrestat on symptomatic diabetic sensory polyneuropathy.
    van Gerven JM; Lemkes HH; van Dijk JG
    J Diabetes Complications; 1992; 6(1):45-8. PubMed ID: 1562758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of diabetic neuropathy].
    Frati-Munari AC; Ariza-Andraca CR
    Gac Med Mex; 1998; 134(1):85-92. PubMed ID: 9658700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy.
    Boulton AJ; Levin S; Comstock J
    Diabetologia; 1990 Jul; 33(7):431-7. PubMed ID: 2119323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicentre trial of the aldose-reductase inhibitor tolrestat, in patients with symptomatic diabetic peripheral neuropathy. North European Tolrestat Study Group.
    Macleod AF; Boulton AJ; Owens DR; Van Rooy P; Van Gerven JM; Macrury S; Scarpello JH; Segers O; Heller SR; Van Der Veen EA
    Diabete Metab; 1992; 18(1):14-20. PubMed ID: 1563531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolrestat in the primary prevention of diabetic neuropathy.
    Giugliano D; Acampora R; Marfella R; Di Maro G; De Rosa N; Misso L; Ceriello A; Quatraro A; D'Onofrio F
    Diabetes Care; 1995 Apr; 18(4):536-41. PubMed ID: 7497865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of the aldose reductase inhibitor tolrestat: studies in healthy young and elderly male and female subjects and in subjects with diabetes.
    Fruncillo R; Troy S; Parker V; Mayersohn M; Hicks D; Kraml M; Battle M; Chiang S
    Clin Pharmacol Ther; 1996 Jun; 59(6):603-12. PubMed ID: 8681485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of an aldose reductase inhibitor on esophageal dysfunction in diabetic patients.
    Kinekawa F; Kubo F; Matsuda K; Fujita Y; Kobayashi M; Funakoshi F; Uchida N; Watanabe S; Tomita T; Uchida Y; Kuriyama S
    Hepatogastroenterology; 2005; 52(62):471-4. PubMed ID: 15816460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the aldose reductase inhibitor, ponalrestat, on diabetic neuropathy.
    Gill JS; Williams G; Ghatei MA; Hetreed AH; Mather HM; Bloom SR
    Diabete Metab; 1990; 16(4):296-302. PubMed ID: 2125013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report.
    Valensi P; Le Devehat C; Richard JL; Farez C; Khodabandehlou T; Rosenbloom RA; LeFante C
    J Diabetes Complications; 2005; 19(5):247-53. PubMed ID: 16112498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A meta-analysis of trials on aldose reductase inhibitors in diabetic peripheral neuropathy. The Italian Study Group. The St. Vincent Declaration.
    Nicolucci A; Carinci F; Cavaliere D; Scorpiglione N; Belfiglio M; Labbrozzi D; Mari E; Benedetti MM; Tognoni G; Liberati A
    Diabet Med; 1996 Dec; 13(12):1017-26. PubMed ID: 8973882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of treatment with an aldose-reductase inhibitor on symptomatic carpal tunnel syndrome in type 2 diabetes.
    Monge L; De Mattei M; Dani F; Sciarretta A; Carta Q
    Diabet Med; 1995 Dec; 12(12):1097-101. PubMed ID: 8750220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional differences in the manifestation of gastrointestinal motor disorders in type 1 diabetic patients with autonomic neuropathy.
    Rosztóczy A; Róka R; Várkonyi TT; Lengyel C; Izbéki F; Lonovics J; Wittmann T
    Z Gastroenterol; 2004 Nov; 42(11):1295-300. PubMed ID: 15558439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.